Advanced search
Publication Cover
Substance Abuse Volume 40, 2019 - Issue 4: Specific disciplines addressing substance use: AMERSA in the 21st century
Journal homepage
324
Views
2
CrossRef citations to date
0
Altmetric
Case Report

Successful treatment with slow-release oral morphine following afentanyl-related overdose: A case report

Gerrit PrinslooBritish Columbia Centre on Substance Use, Vancouver, British Columbia, Canada; ;Department of Family Practice, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; View further author information
, MbChB,
Keith AhamadBritish Columbia Centre on Substance Use, Vancouver, British Columbia, Canada; ;Department of Family Practice, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, Canada; View further author information
, MD &
M. Eugenia SocíasBritish Columbia Centre on Substance Use, Vancouver, British Columbia, Canada; ;Department of Medicine, Faculty of Medicine, University of British Columbia, Vancouver, British Columbia, CanadaCorrespondence[email protected]
ORCID Iconhttp://orcid.org/0000-0003-2556-7049View further author information
, MD, MScORCID Icon
Pages 473-475 | Published online: 04 Mar 2019

References

  • Seth P, Scholl L, Rudd RA, Bacon S. Overdose deaths involving opioids, cocaine, and psychostimulants - United States, 2015-2016. MMWR Morb Mortal Wkly Rep. 2018;67(12):349–358.
  • Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatry. 2015;23(2):63–75.
  • MacArthur GJ, van Velzen E, Palmateer N, et al. Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. Int J Drug Policy. 2014;25(1):34–52.
  • A Guideline for the Clinical Management of Opioid Use Disorder. Vancouver, BC, Canada: British Columbia Centre on Substance Use (BCCSU); 2017. http://www.bccsu.ca/wp-content/uploads/2017/02/BC-OUD-Guidelines_FINAL.pdf. Accessed January 4, 2018.
  • Sustained release oral morphine, injectable hydromorphone, and Prescription Diacetylmorphine for Opioid Use Disorder: Clinical and Cost effectiveness, and guidelines. CADTH rapid response report: summary of abstracts. Ottawa, ON, Canada: CADTH; 2017. https://www.cadth.ca/sustained-release-oral-morphine-injectable-hydromorphone-and-prescription-diacetylmorphine-opioid-0. Accessed Apr 1, 2018.
  • Timko C, Schultz NR, Cucciare MA, Vittorio L, Garrison-Diehn C. Retention in medication-assisted treatment for opiate dependence: a systematic review. J Addict Dis. 2016;35(1):22–35.
  • Sordo L, Barrio G, Bravo MJ, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550
  • Beck T, Haasen C, Verthein U, et al. Maintenance treatment for opioid dependence with slow-release oral morphine: a randomized cross-over, non-inferiority study versus methadone. Addiction. 2014;109(4):617–626.
  • Jegu J, Gallini A, Soler P, Montastruc JL, Lapeyre-Mestre M. Slow-release oral morphine for opioid maintenance treatment: a systematic review. Br J Clin Pharmacol. 2011;71(6):832–843.
  • Ferri M, Minozzi S, Bo A, Amato L. Slow-release oral morphine as maintenance therapy for opioid dependence. Cochrane Database Syst Rev. 2013;(6):CD009879.
  • Hammig R, Kohler W, Bonorden-Kleij K, et al. Safety and tolerability of slow-release oral morphine versus methadone in the treatment of opioid dependence. J Subst Abuse Treat. 2014;47(4):275–281.
  • Falcato L, Beck T, Reimer J, Verthein U. Self-reported cravings for heroin and cocaine during maintenance treatment with slow-release oral morphine compared with methadone: a randomized, crossover clinical trial. J Clin Psychopharmacol. 2015;35(2):150–157.
  • Verthein U, Beck T, Haasen C, Reimer J. Mental symptoms and drug use in maintenance treatment with slow-release oral morphine compared to methadone: results of a randomized crossover study. Eur Addict Res. 2015;21(2):97–104.
  • Socias ME, Wood E. Evaluating slow-release oral morphine to narrow the treatment gap for opioid use disorders. Ann Intern Med. 2018;168(2):141–142.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.